Conclusion

Bioavailable SnF₂ has a well-established history for a wide spectrum of therapeutic oral indications based on a myriad of published research establishing clinical effectiveness, including anti-plaque and anti-gingivitis efficacy. In addition to its known bactericidal/bacteriostatic and acid suppression effects, recent research has discovered a new plaque virulence modulation mechanism in which bioavailable SnF₂ binds with gingival sulcus pathogenic endotoxins to reduce the inflammatory cascade at its inception stage, and thus prevent or reduce the clinical manifestations of gingivitis irrespective of plaque quantity. The most recent SnF₂ dentifrice advancement includes use of the amino acid glycine as a stabilizer for SnF₂, leading to greater SnF₂ biofilm penetration, LPS neutralization and gingival cell recovery as well as rapid and sustained reductions in gingival bleeding. Regular toothbrushing with properly formulated bioavailable chemotherapeutic antimicrobial SnF₂ dentifrice provides an easy to implement strategy not only for patients with existing gingivitis (treatment) but also for those with increased susceptibility or not yet manifesting symptoms (prevention).